Current Emerging Therapy for Amyloidosis Neuropathy

Abstract

nificant
phenotype in the peripheral nervous system. Hereditary amyloidogenic transthyretin (hATTR) neuropathy is typical polyneuropathy
caused by single-nucleotide variants in the gene encoding transthyretin (TTR) and leads to transthyretin misfolding
and systemic deposition of amyloid. One of the clinical hallmarks of hATTR neuropathy is polyneuropathy of the destruction
of the somatic and autonomic peripheral nervous system, leading to loss of autonomy. Progressive amyloid accumulation also
causes multi-organ dysfunction and death. There are many therapeutics that have been proposed and developed in these years.
These therapies aim to reduce or eliminate hATTR from the plasma, stabilize the hATTR to prevent deposition, and dissolute
the amyloid misfolding matrix. Recently, gene therapy strategy is being deployed to treat recessive genetic disorders by eliminating
the expression of the mutated genes. Thus, gene-silencing approaches have been used to manage this amyloidosis neuropathy
in the broad stages and produce some degree of improvement of this disease. Food and Drug Administration (FDA) approved
Inotersen (an antisense oligonucleotide (ASO)) and patisiran (a small interfering ribonucleic acid (siRNA) for the treatment of
hATTR polyneuropathy to suppress hATTR expression. Inotersen, a 2’-O-methoxyethylmodified ASO, which acts by reducing
the production of transthyretin, and has been demonstrated to improve the quality of life in early hereditary transthyretin amyloidosis
polyneuropathy. I here focus on the RNA-targeted therapy with particular emphasis on the molecular mechanisms by
which antisense oligonucleotide can be designed to modulate transthyretin RNA function for being a novel therapy for hereditary
amyloidosis neuropathy.